What type of study is this?

This is a In Silico Study study.

September 10, 2025

"In Silico Development and Evaluation of Doxorubicin Hybrids as Potent Anticancer Agents"

Key Points

Doxorubicin hybrids showed favorable binding affinities in molecular docking, enhancing their potential as anticancer agents.
Predicted toxicity profiles indicate reduced side effects compared to traditional doxorubicin, improving therapeutic safety.
In silico methods were utilized to assess physicochemical properties and pharmacokinetic profiles, optimizing hybrid design.
This work highlights the need for further in vitro and in vivo validation of these doxorubicin hybrids in anticancer therapy.

Abstract

Doxorubicin remains a cornerstone in cancer chemotherapy; however, its clinical utility is hindered by doselimiting toxicities and drug resistance. In this study, novel hybrid derivatives of doxorubicin were computationally designed and evaluated for their anticancer potential using in silico methods. Ligands were constructed using ChemSketch and assessed for physicochemical properties (Molinspiration), pharmacokinetic profiles (SwissADME), and biological activities (PASS). Toxicity was predicted via GUSAR, while molecular docking was performed using AutoDock Vina with key cancer-related protein targets. Docking results indicated favorable binding affinities, particularly with 5zad and 4zqf, suggesting enhanced therapeutic interactions. Visualization of ligand-protein interactions was conducted using Biovia Discovery Studio. This study demonstrates the potential of doxorubicin hybrids as promising leads for further development in anticancer therapy. Further in vitro and in vivo validation is warranted.

Demander à l'IA

Bookmark

View Full Paper